Can This Former Pandemic Star Make a Stunning Comeback?

Once one of the biggest winners of the pandemic era, Moderna (MRNA) saw explosive growth as demand for its COVID-19 vaccine surged worldwide. Between 2020 and 2022, investors who put their belief in this unknown biotech saw astronomical returns. But as pandemic-driven sales faded, the company’s stock and revenue momentum has slowed, leaving investors questioning its next chapter.

Now, with a growing pipeline of new vaccines and therapies in development, Moderna is striving to show that its success was not a fluke and that a new period of growth awaits.